


NITRIC OXIDE (Commentary)**When neonatal central cyanosis is not relieved by ventilation**

The first need when pulmonary artery pressure does not fall after birth, and a baby presents with features of what used to be called a 'persistent fetal circulation', is to get cyanotic congenital heart disease ruled out by an experienced paediatric echocardiographer. While this is being done management, initially, consists of optimising lung expansion, and then optimising left ventricular output and systemic blood pressure before attempting to reduce pulmonary vascular resistance. Babies who are this cyanosed usually require both sedation and paralysis, and many also benefit from treatment with natural surfactant. Sequential ventilator adjustments will help to establish what mean airway pressure provides the best balance between minimising resistance to pulmonary blood flow (see figure) while optimising alveolar ventilation.



It is important to try and determine why desaturated blood is reaching the left side of the heart before instituting treatment. Blood may be passing right-to-left through a patent foramen ovale, or through a patent duct, or passing through the lung without picking up oxygen. There may be a left-to-right shunt between the atria and through the duct, or a right-to-left shunt within the lung – a situation most typically seen in very low birth weight babies with patchy atelectasis or pulmonary interstitial emphysema. Such babies seldom obtain sustained benefit from a pulmonary vasodilator. In term babies without respiratory disease (or with meconium aspiration and asphyxia) cyanosis is usually due to a persistence of the high pulmonary vascular tone normally present before birth. Blood continues to shunt right-to-left across the duct, and a dilated failing right ventricle causes right atrial pressure to rise resulting in further right-to-left flow across the foramen ovale. A chest x-ray may suggest that pulmonary blood flow is sparse, and pulse oximetry may provide evidence of a ductal shunt with saturation in the ("preductal") right arm higher than elsewhere. This persistence of the fetal circulation is now generally called persistent pulmonary hypertension, although the hypertension is usually more relative than absolute.

Once mean airway pressure and left ventricular function have been optimised it may be appropriate to try to manipulate pulmonary vascular tone. A physiological approach should be tried before resorting to drugs. Hypoxia, acidosis and a high arterial $p\text{CO}_2$ (carbon dioxide pressure) may need correction since all increase pulmonary vascular tone. Hyperventilation can cause volume/pressure damage to the lung, and potentially harmful cerebral vasoconstriction, so it may be more appropriate to raise the pH above 7.4 by infusing base. If cyanosis persists and systemic blood pressure is satisfactory then IV tolazoline or epoprostenol (a more expensive vasodilator) should be considered. These will have some effect at once if they are going to work at all. Magnesium sulphate may also be of some value (although no comparative trials have yet been undertaken) but this only seems to work more slowly. However all these agents affect systemic as well as pulmonary vascular tone, and lower systemic as well as pulmonary arterial blood pressure. Intratracheal tolazoline and nebulised epoprostenol have been used experimentally with good effect, and this approach minimises the risk of systemic vasodilatation. Treatment with inhaled nitric oxide has, however, now become the treatment of choice when other treatment strategies fail, even though commercial supplies of the gas now make treatment very expensive.

Use of nitric oxide in term, and near term, babies and in older patients

Nitric oxide treatment has been very widely used in adults with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) for fifteen years, and it often improves oxygenation at least marginally for at least a few days. However a whole series of relatively small randomised trials have failed to provide evidence that use improves survival, and meta-analysis of 12 trials involving 1237 patients published in 2007 showed that while the $\text{PaO}_2/\text{FiO}_2$ ratio improved for a time, it delivered no reduction in pre-discharge hospital mortality, or time on a ventilator, and there was some evidence that use actually increased the risk of renal dysfunction (Achikari *et al.*, 2007) even when the dose used is kept below 20 ppm. On the basis of this evidence the routine use of nitric oxide in adults has now started to decline.

Nitric oxide is however now accepted as being the most effective pulmonary vasodilator in babies of more than 34 weeks gestation. While nitric oxide use does not seem to improve survival, it does reduce the need for ExtraCorporeal Membrane Oxygenation (ECMO). Neither of these strategies should be delayed until the baby is *in extremis*, and prompt referral to a centre capable of providing ECMO should be considered if the oxygenation index (OI) approaches 300, [or 40 if arterial oxygen pressure ($p\text{O}_2$) is being measured in mmHg rather than kPa], and does not fall at least 20% after 4 hours of treatment with nitric oxide. The formula for calculating the oxygenation index is:

$$\text{OI} = \text{mean airway pressure (cm H}_2\text{O)} \times \% \text{ oxygen in inspired air} / \text{post ductal arterial } p\text{O}_2 \text{ (kPa)}$$

Because administration during inter-hospital transfer is not easy, and babies respond badly if treatment is interrupted even briefly once started (even when there seems to have been no response to treatment) use is difficult to justify. In units that lack echocardiographic expertise and ready access to an ECMO facility. The results from seven trials involving 847 babies (NINOS, 1997; Roberts *et al.*, 2007; Wessel *et al.*, 1997; Davidson *et al.*, 1998; Christou *et al.*, 2000; Clark *et al.*, 2000; Field *et al.*, 2006) show that while neonatal treatment with nitric oxide does not reduce mortality it can reduce the number of babies needing ECMO by 40% (Relative risk 0.62 [95% CI 0.52, 0.73]). Six trials (NINOS, 2000; Ellington *et al.*, 2001; Lipkin *et al.*, 2002; Clark *et al.*, 2003; Field *et al.*, 2007; Konduri *et al.*, 2007) have now reported long term outcomes. There is no evidence that treatment with nitric oxide is harmful, but it has not yet been found to do anything to reduce the burden of long term disability, which is often significant in babies who have been as ill as this. Nitric oxide can also be of use in some rather older children.

Use of nitric oxide in babies of less than 34 weeks gestation

Although it is now well established that inhaled nitric oxide can reduce the number of term and near babies requiring ECMO treatment for severe hypoxic respiratory failure, evidence that the drug is of use in the *preterm* baby remains elusive. One influential early trial could find no evidence that giving nitric oxide to preterm babies with severe established lung damage did any good (Subhedar *et al.*, 1997), and later follow up assessment confirmed this (Bennett *et al.*, 2001). The focus since then has been on whether earlier treatment, or even 'preventive' treatment, might be more effective. Unfortunately few of these trials (other than the trials reported by Schreiber and van Meurs) have yet reported what the long term outcome was, and it is increasingly clear that many of the features seen on the cranial ultrasound scans that were done during these trials are relatively poor predictors of long term disability. While serious neurosensory disability can be predicted with some certainty when there is clear evidence of parenchymal brain damage, the *absence* of such an appearance does not guarantee lack of disability two years later (Laptook *et al.*, 2005). Scans done 6–8 weeks after birth are better at picking up periventricular leukomalacia, porencephalic change, and cortical atrophy with or without features of ventriculomegaly, but these were seldom done or reported in these trials.

Late treatment for moderate disease: One recent trial (Ballard *et al.*, 2006) recruited 582 babies who weighed 1250 grams or less at birth (mean gestation 26 ± 1.5 weeks) and who had no evidence of severe intracranial bleeding but who were still ventilator dependent when 7–21 days old, and exposed them to a slowly decreasing dose of nitric oxide for at least 24 days. Most of these babies were only moderately oxygen dependent at recruitment (with an OI that was normally between 5 and 9 when arterial pO₂ is measured in mm Hg units). There was a marginal increase in the number of babies who were alive and no longer oxygen dependent at a postmenstrual age of 36 weeks (43.9 v. 36.8%) and, in a subgroup analysis that had not been pre-specified before the trial began, they found that benefit was only seen in those starting treatment 7–14 days after birth. However, there was no difference in the number surviving (94.6 v. 93.7%), and it is arguable whether treatment of this nature, which is inevitably expensive, can be justified simply because it reduces the length of time a baby remains oxygen dependent (as judged using the Walsh test). Children recruited into the active arm of the trial received rather less medication in the year after discharge, but they were no less likely to need readmission to hospital for respiratory problems later in the first year of life (22.6 v. 21.9%). The outcome of the developmental assessment of these children at two years has not yet been reported.

Early treatment for serious established disease: The merged results from four trials of early 'rescue' treatment involving a total of 650 babies of less than 34 weeks gestation with rather more severe lung disease (babies typically had an OI above 10 at recruitment) in whom a variable period of treatment (Kinsella *et al.*, 1999; Field *et al.*, 2005; Van Meurs *et al.*, 2005; and Dani *et al.*, 2006) was started within 7 days of birth, suggest a marginal *decrease* in the number of babies still oxygen dependent at a postmenstrual age of 36 weeks, but an equally marginal *increase* in the number of deaths. There seemed to be no difference in the incidence of severe (grade 3–4) intraventricular haemorrhage and/or periventricular leukomalacia, and reports on the surviving babies from the Van Meurs trial, and from the smaller Field trial, suggest that use in babies who are already very ill did not improve the long term survival or the neurodevelopmental progress made by those who did survive (Hintz *et al.*, 2007; Field *et al.*, 2007).

Early 'prophylactic' treatment for the ventilator dependent baby:

Schreiber *et al.*, 2003, randomised 207 ventilated babies of less than 34 weeks gestation to receive early inhaled nitric oxide or placebo, and also to treatment with intermittent mandatory ventilation or high-frequency oscillatory ventilation for 7 days before they were three days old. The infants in this single centre study all had a birth weight of less than 2000g (mean 989 grams) and had a median oxygen index (OI) of 7 when recruited, and those randomised to treatment with 5–10 ppm of nitric oxide were less likely to be dead or still oxygen dependent at a postmenstrual age of 36 weeks. They were also less likely to have severe intraventricular haemorrhage. However benefit was most noticeable in those babies who only had moderate respiratory distress when recruited (OI <7), and an unusually large number of the control babies had an intraventricular haemorrhage or were still oxygen dependant at 36

weeks. Those with severe disease seemed to derive little benefit. Findings at follow up were in line with the findings at discharge (Mestan *et al*, 2005).

Kinsella *et al.*, 2006 recruited a further 793 babies of less than 34 weeks gestation who weighed 1250 grams or less at birth (mean 791 grams) from 16 study centres. All were intubated and all were still less than 48 hours old when recruited. Half of those recruited were then randomised to treatment with low dose (5 ppm) nitric oxide for an average of 12 days. Most of the babies only had moderate disease when recruited (mean OI [SD] 5.6 ± 5.9). There was no difference in the primary outcome (death or continued oxygen dependency at a postmenstrual age of 36 weeks), or in any of the individual secondary outcomes, but there was a marginal decrease (17.5 v. 23.9%) in the number of babies with some form of cerebral insult (either severe intraventricular bleeding, or haemorrhagic ventriculomegally or periventricular leukomalacia) in those given continuous low dose nitric oxide for three weeks (or until extubation). However at the Pediatric Academic Societies' Annual meeting in Baltimore in May this year it was announced that no differences were detectable in any of a range of measures of developmental disability in the two trial groups when the children were seen again two years later (Kinsella *et al.*, 2009).

Ballard *et al.*, 2006 recruited 582 babies weighing less than 1250 grams who were still ventilator dependent when 7–21 days old (mean 763 grams) from 21 centres. Babies offered nitric oxide were marginally less likely to be oxygen dependent at 36 weeks post menstrual age (56.1% v. 63.2%) but there were few other differences between the two trial groups. Those present at the meeting in Baltimore in May were told that, as might have been expected since nitric oxide was only started when the baby was at least a week old, there were no differences in the amount of neurodevelopmental impairment two years later (Keller *et al.*, 2009).

The results of a further major trial (the EUNO trial) were announced for the first time at the European Society for Paediatric Research in October 2008. It had recruited 800 babies from 35 centres across Europe. All were less than 29 weeks gestation at birth (mean weight 858 grams and mean gestation 26.5 weeks). Ninety percent of the babies had had antenatal steroids, all had already received surfactant within 12 hours of birth, and 90% were intubated at the time of recruitment. Information on the OI is only available for about half the babies, but the mean value (8.1) did not differ much from that seen in the earlier two trials, but the new trial deliberately excluded babies with severe disease (babies needing more than 50% oxygen to maintain an arterial oxygen saturation of more than 85% two hours after being given surfactant). It found **no** evidence that early low dose treatment with 5 ppm for 7 to 21 (a mean of 16) days did anything to improve survival (85.8% v. 89.5%), or the number of babies alive and no longer in oxygen at 36 weeks (65.3% v. 65.5%). Indeed, in contradiction to what Schreiber and Kinsella had found, there were slightly *more* deaths, and a hint that there had been more deaths with an intracerebral bleed in nitric oxide treated babies of less than 26 weeks gestation.

Conclusion It is now, finally, reasonably clear that offering the very preterm baby early, sustained, low-dose, prophylactic treatment with nitric oxide does almost nothing to increase survival, or to reduce the risk of the baby still being oxygen dependent at 36 weeks. Any final view as to whether early prophylaxis is 'neuroprotective', as the Schreiber and Kinsella trials had tended to suggest, will need to wait until this latest trial is reported in full, but this now looks increasingly unlikely. When the surviving babies in the Schreiber trial were seen for follow up it did look as though the cerebral ultrasound information had correctly predicted what the balance of disability would be in the two trial groups, but this has not always been the case in other trials. It will, therefore, be very important to get follow up information in the children in the other two trials – especially as reliable information on periventricular leukomalacia was not obtained in all the children in the EUNO trial.

These recent reports mean that it has now become very difficult to advocate the **early** prophylactic use of nitric oxide, even in a further trial, at least until such time as the two year outcome of the children who were recruited into the most recent European trial becomes known – especially in the very preterm baby. As for treatment in babies with moderately serious **established** disease 7–14 days after birth (with an OI generally somewhere between 5 and 9), sustained treatment may marginally reduce the number of babies who are still oxygen dependent at 36 weeks, but it does not seem to improve survival (Ballard *et al.*, 2006) or long term outcome (Keller *et al.*, 2009) and there are other, less expensive, ways of reducing chronic oxygen dependency, as the recent caffeine trial showed (Schmidt *et al.*, 2008). Nitric oxide may occasionally be of value in a few babies of less than 34 weeks gestation if there are clear features of persistent pulmonary hypertension (Tanaka *et al.*, 2007), but there is no very little to support more widespread use.

Use where there is clear evidence of pulmonary hypertension: The suggestion that treatment in babies of more than 34 weeks gestation is generally successful, while treatment of babies less mature than this is, at most, of marginal value is, of course, almost certainly an over-simplification and there is one study

(Tanaka *et al.*, 2007) that suggests that treatment with nitric oxide can be of value in babies of less than 34 weeks gestation who have clear evidence of persisting pulmonary hypertension.

Does treatment increase the risk of intracranial bleeding? There has been concern that exposure to nitric oxide might increase the risk of intracerebral bleeding in the very preterm baby, but there seems to be little evidence of this. Indeed two large trials (Schreiber *et al.*, 2003; Kinsella *et al.*, 2006) of early prophylactic treatment have presented sub-group analyses suggesting that early treatment can actually *decrease* the incidence of grade 3–4 intraventricular haemorrhage. Sub-group analyses of this type (especially if not pre-specified) can easily find differences that subsequent trials fail to confirm. On the other hand nitric oxide exposure was associated with a significant *increase* in the number of babies developing a grade III-IV intraventricular haemorrhage among the 420 babies in the van Meurs trial and, on follow up, Hintz *et al.*, 2007 found that more babies so treated did not survive or survived with quite severe cerebral palsy. It will, therefore, be very instructive to see what the outcome of the large, industry funded, EuNO trial that is currently recruiting in Europe turns out to be. This is a trial looking at the value of giving early sustained low dose nitric oxide to babies of less than 29 weeks gestation who have been given surfactant, or found to need an inspired oxygen of 30% or more when offered nasal CPAP (at a pressure of ≥ 4 cm H₂O), within 24 hours of birth. Outcome will be assessed not only when the babies reach a post-menstrual age of 36 weeks, but also two years after they were due to be born.

In the interim we have the illogical situation that many clinicians now find themselves tempted to use nitric oxide as a treatment of last resort when faced with a seriously ill preterm baby because there is nothing to lose and nothing else to do, although trials suggest that such treatment is of little benefit, but remain reluctant to advocate early prophylactic use even though these are the babies where there is most evidence, at the moment, that treatment can be of benefit. One reason for this reluctance must be because sustained early use is extremely expensive. Stark (2006) quotes a figure of \$3,000 a day for the current cost of using nitric oxide in North America, and use in babies offered early 'rescue' treatment to babies who were chronically ventilator dependent 7-14 days in the Ballard trial did not significantly decrease total pre-discharge costs (Zupancic *et al.*, 2009). A second reason may be that the recent Mercier and Kinsella trials found no evidence that early prophylactic use was beneficial. In the mean time simpler, less aggressive, strategies of respiratory support, and the wider use of caffeine citrate (q.v.), look set to do more than nitric oxide to reduce the risk of chronic lung scarring and long term oxygen dependency in the very preterm baby. The case for using nitric oxide in these babies when there is no evidence of persisting pulmonary hypertension is probably going to depend on whether it proves possible to corroborate current claims that such treatment can be 'neuroprotective' and there is, at present, very little evidence of this.

References

- The neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full term and near term infants with hypoxic respiratory failure. *N Engl J Med* 1997;**336**:597–604. [RCT]
- Roberts JD, Fineman J, Morin FC, *et al.* Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. *N Engl J Med* 1997;**336**:605–10. [RCT]
- Wessel DL, Adatia L, Van Marter LJ, *et al.* Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. *Pediatrics* 1997;**100**:e7. [RCT]
- Davidson D, Barefield ES, Kattwinkel J, *et al.* Inhaled nitric oxide treatment of persistent pulmonary hypertension of the newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. *Pediatrics* 1998;**101**:325–34. [RCT]
- Christou H, Van Marter LJ, Wessel DL, *et al.* Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. *Crit Care Med* 2000;**28**:3722–7. [RCT]
- The Franco-Belgian Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. *Lancet* 1999;**354**:1066–71. [RCT] (Erratum 1826.)
- Kinsella JP, Walsh WF, Bose CL, *et al.* Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. *Lancet* 1999;**354**:1061–5. [RCT]
- Kinsella JP, Abman SH. Clinical approach to inhaled nitric oxide therapy in the newborn with hypoxemia. *J Pediatr* 2000;**136**:717-26.
- Clark RH, for the Clinical Inhaled Nitric Oxide Research Group. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. *N Engl J Med* 2000;**342**:469-74. [RCT]
- The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the Neonatal Inhaled Nitric Oxide Study Group (NINOS). *J Pediatr* 2000;**136**:611–7. [RCT]
- Miller OI, Tank SF, Keech A, *et al.* Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. *Lancet* 2000;**356**:1464–9. [RCT]
- Ellinton M, O'Reilly D, Allred EN, *et al.* Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. *Pediatrics* 2001;**107**:1351–6. [RCT]
- Finer NN, Sun JW, Rich W, *et al.* Randomized, prospective study of low-dose versus high-dose inhaled nitric oxide in the neonate with hypoxic respiratory failure. *Pediatrics* 2001;**108**:949–55. [RCT]
- Bennett AJ, Shaw NJ, Gregg JE, *et al.* Neurodevelopmental outcome in high-risk preterm infants treated with inhaled nitric oxide. *Acta Paediatr* 2001;**90**:573–6. [RCT]
- Lipkin PH, Davidson D, Spivak L, *et al.* Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide. *J Pediatr* 2002;**140**:306–10. [RCT]
- Schreiber MD, Gin-Mestan K, Marks JD, *et al.* Inhaled nitric oxide in premature infants with the respiratory distress syndrome. *N Engl J Med* 2003;**349**:2099–107. [RCT]
- Clark RH, Huckaby JL, Keuser TJ, *et al.* Clinical inhaled Nitric Oxide Research Group. Low-dose nitric oxide therapy for persistent pulmonary hypertension: 1-year follow-up. *J Perinatol* 2003;**23**:300–3. [RCT]

- Konduri GG, Solimano A, Sokol G, *et al.* A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. *Pediatrics* 2004;**113**:559–64. [RCT]
- Lorch SA, Cnaan A, Barnhart. Cost-effectiveness of inhaled nitric oxide for the management of persistent pulmonary hypertension of the newborn. *Pediatrics* 2004;**114**:417–26.
- Walshe MC, Yao Q, Gettner P, *et al.* Impact of a physiologic definition on bronchopulmonary dysplasia rates. *Pediatrics* 2005;**114**:1305–11.
- Hascoet JM, Fresson J, Claris O, *et al.* The safety and efficacy of nitric oxide therapy in premature infants. *J Pediatr* 2005;**146**:318–23. [RCT]
- Finer NN. Inhaled nitric oxide for preterm infants: a therapy in search of an indication? The search continues. [Editorial] *J Pediatr* 2005;**146**:301–3.
- Field D, Elbourne D, Truesdale A, *et al.* Neonatal ventilation with inhaled nitric oxide versus ventilatory support without nitric oxide for preterm infants with severe respiratory failure: the INNOVO multicentre randomised controlled trial (ISRCTN 17821339). *Pediatrics* 2005;**115**:926–36. [RCT]
- Van Meurs KP, Wright LL, Ehrenkranz RA, *et al.* Inhaled nitric oxide for premature infants with severe respiratory failure. *N Engl J Med* 2005;**353**:13–22. [RCT]
- Mestan KK, Marks JD, Hecox K, *et al.* Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. *N Engl J Med* 2005;**353**:23–2. [RCT]
- Martin RJ, Walsh MC. Inhaled nitric oxide for preterm infants – who benefits ? [Editorial] *N Engl J Med* 2005;**353**:82–4.
- Laptook AR, O’Shea TM, Shankaran SS, *et al.* Adverse neurodevelopmental outcomes among extremely low birth weight infants with a normal head ultrasound: prevalence and antecedents. *Pediatrics* 2005;**115**:673–80.
- Dani C, Bertini G, Pezzati M, *et al.* Inhaled nitric oxide in very preterm infants with severe respiratory distress syndrome. *Acta Paediatr* 2006;**95**:1116–23. [RCT]
- Ahluwalia J, Tooley J, Cheema I, *et al.* A dose response study of inhaled nitric oxide in hypoxic respiratory failure in preterm infants. *Early Hum Dev* 2006;**82**:477–83.
- Ballard RA, Truog WE, Cnaan A, *et al.* Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. *N Engl J Med* 2006;**355**:343–53. [RCT] (See also correction 2007;**357**:1444–5.)
- Kinsella JP, Cutter GC, Walsh WF, *et al.* Early inhaled nitric oxide therapy in premature newborns with respiratory failure. *N Engl J Med* 2006;**355**:354–64. [RCT]
- Stark AR. Inhaled NO for preterm babies – getting to Yes ? [Editorial] *N Engl J Med* 2006;**355**:404–6.
- Konduri GG, Vohr B, Robertson C, *et al.* Early inhaled nitric oxide therapy for term and near term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up. *J Pediatr* 2007;**150**:235–40. [RCT]
- Field D, Elbourne D, Hardy P, *et al.* Neonatal ventilation with inhaled nitric oxide vs. ventilatory support without inhaled nitric oxide for infants with severe respiratory failure at or near term: the INNOVO multicentre randomised controlled trial. *Neonatology* 2007;**91**:73–82. [RCT]
- Dewhurst C, Harigopal S, Subhedar N. Recent advances in inhaled nitric oxide therapy in neonates: a review of the evidence. *Infant* 2007;**3**:69–75. [SR]
- Adhikari NKJ, Burns KEA, Friedrich JO, *et al.* Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. *BMJ* 2007;**334**:779–82. [SR] (See also 757–8.)
- Van Meurs KP, Hintz SR, Ehrenkranz RA, *et al.* Inhaled nitric oxide in infants >1500 g and <34 weeks gestation with severe respiratory failure. *J Perinatol* 2007;**27**:347–52. [RCT]
- Hintz SR, van Meurs KP, Perriit R, *et al.* Neurodevelopmental outcomes of premature infants with severe respiratory failure enrolled in a randomized controlled trial of inhaled nitric oxide. *J Pediatr* 2007;**151**:16–22. [RCT] (See also 10–5.)
- Tanaka Y, Hayashi T, Kitajima H, *et al.* Inhaled nitric oxide therapy decreases the risk of cerebral palsy in preterm infants with persistent pulmonary hypertension of the newborn. *Pediatrics* 2007;**119**:1159–64.
- Barrington KJ, Finer NN. Inhaled nitric oxide for preterm infants: a systematic review. *Pediatrics* 2007;**120**:1088–99. [SR] (See also correction 2008;**121**:451, and correspondence **121**:1287–9.)
- Dani C, Bertini G. Inhaled nitric oxide for the treatment of preterm babies with respiratory distress syndrome. [Review] *Neonatology* 2008;**94**:87–95.
- Schmidt B, Roberts R, Millar D, *et al.* Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. *Neonatology* 2008;**93**:284–7
- Huddy CI, Bennett CC, Hardy P, *et al.* The INNOVO multicentre randomized controlled trial: neonatal ventilation with inhaled nitric oxide versus ventilatory support without nitric oxide for severe respiratory failure in preterm infants: follow up at 4–5 years. *Arch Dis Child* 2008;**93**:F430–5. [RCT]
- Hibbs AM, Walsh MC, Martin RJ, *et al.* One-year respiratory outcomes of preterm infants enrolled in the nitric oxide (to prevent) chronic lung disease trial. *J Pediatr* 2008;**153**:525–9. [RCT]
- Keller RL, Walsh R, Vittinghoff L, *et al.* Response to inhaled nitric oxide (iNO) and neurodevelopmental impairment (NDI) in NO CLD. [Abstract] *Proceedings of the Pediatric Academic Societies Annual Meeting, Baltimore, 2009 E-PAS* 2009:2155:7 [RCT]
- Kinsella JP. Inhaled nitric oxide in the term newborn. [Review] *Early Hum Devel* 2008;**84**:709–16.
- Kinsella JP, Cutter GR, Walsh WF, *et al.* Outcomes of premature infants enrolled in the early inhaled nitric oxide for prevention of lung disease trial. [Abstract] *Proceedings of the Pediatric Academic Societies Annual Meeting, Baltimore, 2009 E-PAS* 2009:2155:6 [RCT]
- Watson RS, Clermont G, Kinsella JP, *et al.* Clinical and economic effects of INO in premature newborns with respiratory failure at 1 year. *Pediatrics* 2009;**124**:1333–43. [RCT]
- Keller RL, Walsh R, Vittinghoff L, *et al.* Response to inhaled nitric oxide (iNO) and neurodevelopmental impairment (NDI) in NO CLD. [Abstract] *Proceedings of the Pediatric Academic Societies Annual Meeting, Baltimore, 2009 E-PAS* 2009:2155:7 [RCT]
- Mercier JC, Hummler H, Durrmeyer X, *et al.* Inhaled nitric oxide (INO) for the prevention of bronchopulmonary dysplasia (BPD) in preterm infants. The EUNO trial. [Abstract] *Proceedings of the Pediatric Academic Societies Annual Meeting, Baltimore, 2009 E-PAS* 2009:3212:5 [RCT]
- Zupancic JAF, Hibbs AM, Palerma L, *et al.* Economic evaluation of inhaled nitric oxide in preterm infants undergoing mechanical ventilation. *Pediatrics* 2009;**124**:1325–32. [RCT]

Commentary first posted September 2005;

Updated November 2009